Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
Items 101–200 of 628
Silva, S., Bicker, J., Falcão, A. C., & Fortuna, A. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111975 · Cited by 54
Pagonabarraga, J., Álamo, C., Castellanos, M., Díaz, S., & Manzano, S. (2023) · Brain Sciences · doi:10.3390/brainsci13020318 · Cited by 52
Vortioxetine: A Review of Its Use in Major Depressive Disorder
Garnock-Jones, K. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0195-x · Cited by 51
“4 nM) [4, 6]; it has a much lower affinity to the human norepinephrine (Ki = 113 nM) and dopamine (Ki [ 1,000 nM) transporters [4].”
BackgroundDeardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 49
“The SNRIs duloxetine, venlafaxine and desvenlafaxine all preferentially inhibit 5-HT reuptake compared to norepinephrine (NE) reuptake.”
BackgroundInfluentialChristensen, M. C., Loft, H., & McIntyre, R. S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.081 · Cited by 46
Catalytic Electrophilic C–H Sulfenylation of Indoles with Disulfides under Ball Milling
Qin, J., Zuo, H., Ni, Y., Yu, Q., & Zhong, F. (2020) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.0c03942 · Cited by 48
5HT3 receptors: Target for new antidepressant drugs
Gupta, D., Prabhakar, V., & Radhakrishnan, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.001 · Cited by 51
Zajdel, P., Kurczab, R., Grychowska, K., Satała, G., Pawłowski, M., & Bojarski, A. J. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.043 · Cited by 45
The therapeutic potential of 5-HT1A receptors: a patent review
Lacivita, E., Pilato, P. D., Giorgio, P. D., Colabufo, N. A., Berardi, F., Perrone, R., & Leopoldo, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.703654 · Cited by 45
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45
Inoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
Berhan, A., & Barker, A. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0276-x · Cited by 43
“serotonin transporter [6,7].”
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., & Chen, Y. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2371 · Cited by 44
“In vitro studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundMillan, M. J., Rivet, J.-M., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 45
“…profile that embraced not only 5-HT1A receptor agonist properties, but also partial agonism at 5-HT1B receptors as well as antagonist properties at 5-HT1D, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011; Mørk et al., 2012; Pehrson et al., 2013; Riga et al., 2016; Sanchez et al., 2015).”
BackgroundAdamo, D., Pecoraro, G., Coppola, N., Calabria, E., Aria, M., & Mignogna, M. D. (2020) · Oral Diseases · doi:10.1111/odi.13602 · Cited by 50
Šagud, M., Perković, M. N., Vuksan‐Ćusa, B., Maravić, A., Štrac, D. Š., Peleš, A. M., Živković, M., Kušević, Z., & Pivac, N. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4364-0 · Cited by 46
Regioselective C–H Thioarylation of Electron-Rich Arenes by Iron(III) Triflimide Catalysis
Dodds, A. C., & Sutherland, A. J. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00448 · Cited by 43
Recent Metal-Catalyzed Methods for Thioether Synthesis
Fleischer, I., Geiger, V. J., Oechsner, R. M., & Gehrtz, P. (2022) · Synthesis · doi:10.1055/a-1914-1231 · Cited by 43
Wang, Y., Zhang, X., Liu, H., Chen, H., & Huang, D. (2016) · Organic Chemistry Frontiers · doi:10.1039/c6qo00451b · Cited by 42
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 45
Nomikos, G. G., Tomori, D., Zhong, W., Affinito, J., & Palo, W. A. (2016) · CNS Spectrums · doi:10.1017/s1092852916000626 · Cited by 43
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
Romanelli, M. N., Braconi, L., Gabellini, A., Manetti, D., Marotta, G., & Teodori, E. (2023) · Molecules · doi:10.3390/molecules29010068 · Cited by 40
The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
Florea, I., Loft, H., Danchenko, N., Rive, B., Brignone, M., Merikle, E., Jacobsen, P. L., & Sheehan, D. V. (2017) · Brain and Behavior · doi:10.1002/brb3.622 · Cited by 40
Taciak, P., Lysenko, N., & Mazurek, A. P. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.07.011 · Cited by 45
“Development of this kind of drugs resulted from the discovery that pindolol, a partial 5-HT1A receptor agonist, augments the antidepressant activity of SSRIs [93].”
BackgroundWestrich, L., Haddjeri, N., Dkhissi-Benyahya, O., & Sánchez, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.015 · Cited by 40
Zhang, W., Huang, M., Zou, Z., Wu, Z., Ni, S., Kong, L., Zheng, Y., Wang, Y., & Pan, Y. (2020) · Chemical Science · doi:10.1039/d0sc06446g · Cited by 39
The brain serotonin system in autism
Rodnyy, A. Y., Kondaurova, E. M., Tsybko, A. S., Popova, N. K., Kudlay, D. A., & Naumenko, V. S. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0055 · Cited by 46
Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges
Fan, H., Chiang, K.-L., Chang, K., Chen, C., & Tsai, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065270 · Cited by 43
Pehrson, A. L., Jeyarajah, T., & Sanchez, C. (2016) · CNS Spectrums · doi:10.1017/s1092852915000486 · Cited by 36
Jacobsen, P. L., Nomikos, G. G., Zhong, W., Cutler, A. J., Affinito, J., & Clayton, A. H. (2019) · CNS Spectrums · doi:10.1017/s1092852919000750 · Cited by 46
Findling, R. L., DelBello, M. P., Zuddas, A., Emslie, G. J., Ettrup, A., Petersen, M. L., Schmidt, S. N., & Rosén, M. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.01.004 · Cited by 50
Christensen, M. C., Schmidt, S. N., & Grande, I. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.06.024 · Cited by 39
Stahl, S. M. (2015) · CNS Spectrums · doi:10.1017/s1092852915000346 · Cited by 40
“By contrast, vortioxetine blocks the 5HT3 receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced (Figure 3C).(2,8)”
BackgroundFiorillo, A., Carpiniello, B., Giorgi, S. D., Pia, S. L., Maina, G., Sampogna, G., Spina, E., Tortorella, A. A. V., & Vita, A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00493 · Cited by 39
Fernandes, R. A., Bhowmik, A., & Yadav, S. S. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02035d · Cited by 36
An Overview of Vortioxetine: (Academic Highlights)
Schatzberg, A. F., Blier, P., Culpepper, L., Jain, R., Papakostas, G. I., & Thase, M. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14027ah1 · Cited by 36
Brivio, P., Corsini, G., Riva, M. A., & Calabrese, F. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.006 · Cited by 38
Pandey, A. K., Chand, S., Singh, R. P., Kumar, S., & Singh, K. N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00472 · Cited by 35
Betry, C., Overstreet, D. H., Haddjeri, N., Pehrson, A. L., Bundgaard, C., Sánchez, C., & Mørk, A. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.011 · Cited by 36
Self-citationPapakostas, G. I., Nielsen, R. Z., Dragheim, M., & Tonnoir, B. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.017 · Cited by 36
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Staroń, J., Bugno, R., Hogendorf, A. S., & Bojarski, A. J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1514011 · Cited by 35
“Buspirone [13] (agonist at 5-HT1AR, Ki = 20 nM), vortioxetine [14] (agonist at 5-HT1AR Ki = 15 nM, 5-HT3R Ki = 3.”
The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor
Zarkadas, E., Zhang, H., Cai, W., Effantin, G., Perot, J., Neyton, J., Chipot, C. J., Schoehn, G., Dehez, F., & Nury, H. (2020) · Structure · doi:10.1016/j.str.2020.07.004 · Cited by 34
Mansari, M. E., Lecours, M., & Blier, P. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3870-9 · Cited by 36
“…5-HT1A receptors on pyramidal neurons was unaltered, this enhancement must therefore be attributable to an elevation of synaptic 5-HT in their vicinity, as vortioxetine shows a very weak affinity for 5- HT1A receptors in rats when compared to humans (Bang-Andersen et al. 2011; Mørk et al. 2012).”
BackgroundRecent Advances and Challenges of the Drugs Acting on Monoamine Transporters
Xue, W., Fu, T., Zheng, G., Tu, G., Zhang, Y., Yang, F., Tao, L., Yao, L., & Zhu, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009123218 · Cited by 34
Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway
Lv, G., Wang, T., Zhu, H., Wang, H., Sun, W. C., & Zhao, L. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12944 · Cited by 33
Synthesis of Organosulfur and Related Heterocycles under Mechanochemical Conditions
Chatterjee, T., & Ranu, B. C. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c01454 · Cited by 33
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
Adamo, D., Calabria, E., Coppola, N., Pecoraro, G., & Mignogna, M. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034320 · Cited by 38
Christensen, M. C., McIntyre, R. S., Florea, I., Loft, H., & Fagiolini, A. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000936 · Cited by 35
“Vortioxetine affects all these targets at clinically relevant doses; however, the affinity of vortioxetine varies between serotonin receptor types, resulting in dose-dependent recruitment of different mechanisms.(30) With regard to the serotonin reuptake transporter, a dose-related increase in occupancy at steady-stat…”
BackgroundPET as a Translational Tool in Drug Development for Neuroscience Compounds
Varrone, A., Bundgaard, C., & Bang‐Andersen, B. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2548 · Cited by 34
Self-citationTherapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation
Fukuyama, K., Motomura, E., & Okada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032070 · Cited by 36
“Reference [27] [28,29] [30] [31,32] [33,49] [34] [35] [29,36] [37] [38]”
BackgroundBobo, W. V., Kelliny, M., Croarkin, P. E., & Moore, K. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s55313 · Cited by 34
“6 nM).(25,26) This property is believed to be the principal mechanism underlying the antidepressive effect of vortioxetine and numerous other antidepressants.”
BackgroundChen, G., Zhang, W., & Serenko, M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.456 · Cited by 33
“In vitro studies indicate that vortioxetine is a 5-HT3A, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1Breceptor partial agonist, a 5-HT1Areceptor agonist, and an inhibitor of the 5-HT transporter.(16,17) In vivo studies in rats demonstrated that vortioxetine enhances levels of serotonin, noradrenaline, dopamine, acet…”
BackgroundBinding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter.
Andersen, J., Ladefoged, L. K., Wang, D.-Y., Kristensen, T. N. B., Bang-Andersen, B., Kristensen, A., Schiøtt, B., & Strømgaard, K. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00225 · Cited by 26
Self-citationOkada, M., Matsumoto, R., Yamamoto, Y., & Fukuyama, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031351 · Cited by 34
“2 nM) and olanzapine (Ki = 365 nM) to 5-HT7R [70,71], the affinity of vortioxetine to rat 5-HT7R (Ki = 200 nM) is significantly lower than that to human 5-HT7R (Ki = 19 nM) [39,40], but the present results suggest that vortioxetine was able to suppress rat 5-HT7R function in vivo.”
BackgroundResultInfluentialWilson, S., Højer, A.-M., Buchberg, J., Areberg, J., & Nutt, D. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115599387 · Cited by 32
Bucki, A., Marcinkowska, M., Śniecikowska, J., Więckowski, K., Pawłowski, M., Głuch‐Lutwin, M., Gryboś, A., Siwek, A., Pytka, K., Jastrzębska‐Więsek, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00839 · Cited by 32
Okada, M., Okubo, R., & Fukuyama, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246235 · Cited by 32
“6 nM) but a lower affinity to 5-HT1AR (Ki = 230 nM) or 5-HT7R (Ki = 200 nM) [11,12].”
BackgroundChristensen, M. C., Schmidt, S. N., & Grande, I. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221090627 · Cited by 34
Santos‐García, D., Losada, M. G. A., Hernando, I. C., Cabo, I., Baña, R. M. Y., Redondo, R. A., González, J. M. P., Bartolomé, C. C., Painceiras, M. J. F., Alvarado, M. C. Í., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12111466 · Cited by 32
“Vortioxetine has different mechanisms of action; it is a SERT inhibitor; antagonist of 5-HT3, 5-HT7, 5-HTID; partial agonist of 5-HT1B; and a full agonist of 5-HT1A [7].”
BackgroundJacobsen, P. L., Harper, L., Chrones, L., Chan, S., & Mahableshwarkar, A. R. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000081 · Cited by 29
“A number of investigations in vivo have demonstrated that vortioxetine increases extracellular levels of serotonin, norepinephrine, dopamine, histamine, and acetylcholine in the rat forebrain, as well as potentially modulates glutamate neurotransmission by its activity at the various serotonin receptors (Bang-Andersen…”
BackgroundBrignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Guillén-Ruiz, G., Cueto‐Escobedo, J., Limón-Vázquez, A. K., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2024) · Biomedicines · doi:10.3390/biomedicines12122744 · Cited by 42
“Vortioxetine, one of the drugs recently approved by the FDA, inhibits 5-HT reuptake by inhibiting its transporter and has a high affinity for several types of 5-HT receptors [63].”
Adair, M., Christensen, M. C., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.074 · Cited by 31
Kall, M. A., Rohde, M., & J⊘rgensen, M. (2015) · Bioanalysis · doi:10.4155/bio.15.207 · Cited by 30
Self-citationEffectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Vieta, E., Loft, H., & Florea, I. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.012 · Cited by 30
Dale, E., Grunnet, M., Pehrson, A. L., Frederiksen, K., Larsen, P. H., Nielsen, J., Stensbøl, T. B., Ebert, B., Yin, H., Lu, D., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2017.12.025 · Cited by 27
“…of MDD. Vortioxetine is a multimodal antidepressant that acts as an inhibitor at the serotonin (5-HT) transporter (SERT), an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-HT3 and 5-HT7 receptors (Bang-Andersen 2011, Sanchez et al., 2015).”
Self-citationBinding of the Amphetamine-like 1-Phenyl-piperazine to Monoamine Transporters
Severinsen, K., Kraft, J. F., Koldsø, H., Vinberg, K. A., Rothman, R. B., Partilla, J. S., Wiborg, O., Blough, B. E., Schiøtt, B., & Sinning, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300040f · Cited by 30
Uldam, H. K., Juhl, M., Pedersen, H., & Dalgaard, L. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040428 · Cited by 29
“During investigation of the disposition of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide (Lu AA21004, 1) as a novel multimodal antidepressant agent under development for treatment of depression (Bang-Andersen et al., 2011) in humans, two major metabolites were observed in plasma and urine.”
BackgroundInteractions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells
Simmler, L. D., & Liechti, M. E. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_20 · Cited by 31
Riga, M. S., Teruel‐Martí, V., Sánchez, C., Celada, P., & Artigas, F. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.024 · Cited by 32
“…different species and systems, both observations support the view that 5-HT3-R blockade may evoke cellular/molecular actions independent of the presence of 5-HT. VORwas characterized in vitro as a high affinity antagonist at rat and human 5-HT3A-R (Bang-Andersen et al., 2011; Sanchez et al., 2012).”
Thase, M. E., Danchenko, N., Brignone, M., Florea, I., Diamand, F., Jacobsen, P. L., & Vieta, E. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.05.009 · Cited by 33
“Vortioxetine inhibits the 5-HT transporter and acts as an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and an agonist at 5-HT1A receptors (Bang-Andersen et al., 2011; Westrich et al., 2012).”
Inoue, T., Nishimura, A., Sasai, K., & Kitagawa, T. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12623 · Cited by 33
“Vortioxetine is a 5-HT3, 5-HT7, and 5HT1D receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist, in addition to a 5-HT transporter inhibitor.(8,9) Nonclinical data suggest that vortioxetine modulates direct and indirect multiple neurotransmitters in the brain, including serotonin, norepinep…”
BackgroundWang, Y., Nomikos, G. G., Karim, A., Munsaka, M., Serenko, M., Liosatos, M., & Harris, S. I. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.51 · Cited by 29
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 31
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Vortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 29
“This mechanism leads to increased levels of serotonin, noradrenaline, dopamine, acetylcholine, and histamine.(17)”
BackgroundFenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain
Yang, K., Stepanov, V., Martinsson, S., Ettrup, A., Takano, A., Knudsen, G. M., Halldin, C., Farde, L., & Finnema, S. J. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx051 · Cited by 27
Leiser, S. C., Iglesias-Bregna, D., Westrich, L., Pehrson, A. L., & Sánchez, C. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115592347 · Cited by 28
“…is an antagonist at the 5-HT3 receptor ligand-gated ion channel, a 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin transporter (SERT) inhibitor in vitro (Bang-Andersen et al., 2011; Sanchez et al., 2015).”
BackgroundCurrent and Future Challenges in GPCR Drug Discovery
Topiol, S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7465-8_1 · Cited by 29
Drug interactions with vortioxetine, a new multimodal antidepressant
Spina, E., & Santoro, V. (2015) · Rivista di psichiatria · doi:10.1708/2040.22160 · Cited by 29
Jeong, H. W., Yoon, K. H., Lee, C. H., Moon, Y. S., & Kim, D. H. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.2.311 · Cited by 26
“the treatment of major depressive disorder (MDD) with direct effects on serotonin (5-HT) receptor activity and 5-HT transporter inhibition [14,15].”
BackgroundLi, Z., Liu, S., Wu, Q., Li, J., Yang, Q., Wang, X., Peng, P., Wang, Q., Liu, Y., Li, M., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad018 · Cited by 30
“The novel multimodal antidepressant vortioxetine modulates several neurotransmitter systems by directly modulating serotonin receptor and inhibiting the serotonin transporter (Bang-Andersen et al., 2011; Mork et al., 2012).”
BackgroundHuang, L., Xu, H., Yang, Z.-Y., Zheng, Y., & Liu, H. (2014) · Steroids · doi:10.1016/j.steroids.2013.12.004 · Cited by 26
Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Vellante, F., Fornaro, M., Fiengo, A. L. C., Mazza, M., Vecchiotti, R., et al. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1173545 · Cited by 28
“However, the affinity for β1 receptor could not be at present translated to an obvious pharmacology in vivo [97].”
BackgroundWaller, J. A., Chen, F., & Sánchez, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.012 · Cited by 25
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
Zugliani, M. M., do Cabo, M. C., Nardi, A. E., Perna, G., & Freire, R. C. R. (2019) · Psychiatry Investigation · doi:10.30773/pi.2018.12.21.1 · Cited by 28
Chu, X., Xie, T., Wang, Y., Li, X.-R., Rao, W., Xu, H., & Shen, Z. (2020) · Chemical Communications · doi:10.1039/d0cc03303k · Cited by 25
Ding, Y., Xie, P., Zhu, W., Xu, B., Zhao, W., & Zhou, A. (2016) · RSC Advances · doi:10.1039/c6ra18136h · Cited by 25
Lacivita, E., Niso, M., Hansen, H. D., Pilato, P. D., Herth, M. M., Lehel, S., Ettrup, A., Montenegro, L., Perrone, R., Berardi, F., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.016 · Cited by 24
Fu, J., & Chen, Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3633-z · Cited by 24
Ngen, C. C., Zain, A. M., Hemrungrojn, S., Ung, E. K., Kwansanit, P., Yong, K. C. A., Chong, M. S. W., Inpa, C., Yen, T. H., Yeoh, B. B. D., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1477746 · Cited by 25
Shalimova, A. A., Babasieva, V. S., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Mwinyi, J. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0157 · Cited by 28
Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity
Sun, X., Li, N., Zhong, P., Chen, L., & Sun, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01271 · Cited by 24
Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors
Sparling, B. A., & DiMauro, E. F. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.073 · Cited by 23
Vortioxetine for the treatment of major depressive disorder
Tritschler, L., Felice, D., Colle, R., Guilloux, J., Corruble, E., Gardier, A. M., & David, D. J. P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.950655 · Cited by 24
Filippis, S. D., Martinotti, G., Nicoletti, F., Mastrostefano, A., Trovini, G., Pugliese, A., & Nicola, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240827165327 · Cited by 23
“Vortioxetine is a multimodal antidepressant acting as a SERT inhibitor, a full agonist of 5-HT1A receptors, a partial agonist of 5-HT1B receptors, and an antagonist of 5-HT1D, 5-HT3, and 5-HT7 receptors [201, 202].”
Liu, L., Cao, N., Ma, X.-L., Xiong, K., Sun, L., Zou, Q., & Yao, L. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.08.028 · Cited by 22
Chen, G., Nomikos, G. G., Affinito, J., & Zhao, Z. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0389-0 · Cited by 22
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.